Results 141 to 150 of about 4,214 (170)
Some of the next articles are maybe not open access.
Emerging role of immunoproteasomes in pathophysiology
Immunology & Cell Biology, 2016The immunoproteasome is a proteasome variant that is found only in jawed vertebrates. It is responsible for degrading intracellular proteins to generate a major source of peptides with substantial major histocompatibility complex I binding affinity. The immunoproteasome also has roles in T‐cell survival, differentiation and proliferation in various ...
Gagandeep, Kaur, Sanjay, Batra
openaire +2 more sources
Immunoproteasome-Specific Inhibitors and Their Application
2012Immunoproteasomes (IPs) containing the interferon-inducible subunits β1i (LMP2), β2i (MECL-1), and β5i (LMP7) alter proteasomal cleavage preference, optimise the generation of peptide ligands of MHC class I molecules, alter cytokine profile, influence T-helper cell differentiation, and play a role in T-cell survival.
Michael, Basler, Marcus, Groettrup
openaire +2 more sources
Immunoproteasom: drug development for xenotransplantation
Xenotransplantation, 2012The majority of cellular proteins are degraded by proteasomes within the ubiquitin‐proteasome ATP‐dependent degradation pathway. Products of proteasomal activity are short peptides which are further hydrolysed by proteases to single amino acid. Some peptides though can escape the degradation, being selected and uptaken by MHC class I molecules for ...
openaire +1 more source
Role of immunoproteasomes and thymoproteasomes in health and disease
Pathology International, 2021The proteasome is a multisubunit protease that degrades intracellular proteins into small peptides. Besides playing a pivotal role in many cellular processes indispensable for survival, it is involved in the production of peptides presented by major histocompatibility complex class I molecules.
openaire +2 more sources
Modulation of immunoproteasome subunits by liposomal lipid A
Vaccine, 2008Liposomes are phospholipid vesicles that have been used as carriers of antigens and adjuvants. Lipid A, the endotoxic moiety of Gram-negative bacterial lipopolysaccharide is a potent adjuvant and incorporation into liposomes essentially reduces the endotoxic activity of lipid A.
Nicholas J, Steers +2 more
openaire +2 more sources
The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets, 2014Remarkable successes with the FDA-approved proteasome inhibitors bortezomib (Velcade(®)) and carfilzomib (Kyprolis(®)) have proved that the proteasome is an effective target for the treatment of multiple myeloma. In other hematological malignancies, however, clinical trials of proteasome-targeting drugs have shown generally disappointing results to ...
Zachary, Miller +2 more
openaire +2 more sources
Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes
ChemMedChem, 2019AbstractThe development of immunoproteasome‐selective inhibitors is a promising strategy for treating hematologic malignancies, autoimmune and inflammatory diseases. In this context, we report the design, synthesis, and biological evaluation of a new series of amide derivatives as immunoproteasome inhibitors.
Roberta Ettari +8 more
openaire +3 more sources
Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors
Cells, 2022Christopher J Kirk, Kirk Christopher J
exaly